| Vinh Nguyen, MD | |
|
2451 Grant Ave, Philadelphia, PA 19114-1031 | |
| (215) 934-3471 | |
| Not Available |
| Full Name | Vinh Nguyen |
|---|---|
| Gender | Male |
| Speciality | Family Medicine |
| Location | 2451 Grant Ave, Philadelphia, Pennsylvania |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1164045720 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | MD482825 (Pennsylvania) | Primary |
| Entity Name | Harbor Health Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881692366 PECOS PAC ID: 0345146213 Enrollment ID: O20040223000221 |
News Archive
Although the value of vaccines for COVID-19 may seem obvious, government action and investment in vaccines have not been commensurate with the enormous scale of benefits they offer, argue Juan Camilo Castillo and colleagues in this Policy Forum.
Sun Pharmaceutical Industries Ltd. today announced that the Hart-Scott-Rodino (HSR) Act waiting period in connection with the Tender Offer by Alkaloida Chemical Company Exclusive Group Ltd. (Alkaloida), a subsidiary of Sun, for all outstanding Ordinary Shares of Taro Pharmaceutical Industries Ltd. (Taro) expired on September 11, 2009. As of September 12, 2009, the HSR condition to the Offer is satisfied.
Talecris Biotherapeutics, Inc. announced today that it was granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the development of an aerosol formulation of Alpha1-Proteinase Inhibitor (Human, A1PI) to treat congenital alpha1-antitrypsin (AAT) deficiency. AAT deficiency is a chronic, hereditary condition that increases the risk of certain diseases, especially emphysema, which typically emerges in the fourth decade of life. Currently, there are no approved, inhaled treatments available for the treatment of AAT deficiency.
Pfizer Inc and UCB Pharma today announced the approval of a new chewable formulation of Zyrtec® (cetirizine HCl) for the treatment of seasonal and perennial allergic rhinitis (inflammation of the nasal passages) and chronic idiopathic urticaria (itching and hives of unknown causes) in children aged two years and older. The approval by the US Food and Drug Administration makes Zyrtec the first and only prescription antihistamine available in both syrup and chewable form.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Vinh Nguyen, MD 3307 Aldine St, Philadelphia, PA 19136-3801 Ph: () - | Vinh Nguyen, MD 2451 Grant Ave, Philadelphia, PA 19114-1031 Ph: (215) 934-3471 |
News Archive
Although the value of vaccines for COVID-19 may seem obvious, government action and investment in vaccines have not been commensurate with the enormous scale of benefits they offer, argue Juan Camilo Castillo and colleagues in this Policy Forum.
Sun Pharmaceutical Industries Ltd. today announced that the Hart-Scott-Rodino (HSR) Act waiting period in connection with the Tender Offer by Alkaloida Chemical Company Exclusive Group Ltd. (Alkaloida), a subsidiary of Sun, for all outstanding Ordinary Shares of Taro Pharmaceutical Industries Ltd. (Taro) expired on September 11, 2009. As of September 12, 2009, the HSR condition to the Offer is satisfied.
Talecris Biotherapeutics, Inc. announced today that it was granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the development of an aerosol formulation of Alpha1-Proteinase Inhibitor (Human, A1PI) to treat congenital alpha1-antitrypsin (AAT) deficiency. AAT deficiency is a chronic, hereditary condition that increases the risk of certain diseases, especially emphysema, which typically emerges in the fourth decade of life. Currently, there are no approved, inhaled treatments available for the treatment of AAT deficiency.
Pfizer Inc and UCB Pharma today announced the approval of a new chewable formulation of Zyrtec® (cetirizine HCl) for the treatment of seasonal and perennial allergic rhinitis (inflammation of the nasal passages) and chronic idiopathic urticaria (itching and hives of unknown causes) in children aged two years and older. The approval by the US Food and Drug Administration makes Zyrtec the first and only prescription antihistamine available in both syrup and chewable form.
› Verified 4 days ago
Srikar Vegesna, Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2118 Cottman Ave, Philadelphia, PA 19149 Phone: 215-342-3020 Fax: 215-342-3653 | |
Chelsea Tiffany Salas-tam, Family Medicine Medicare: Medicare Enrolled Practice Location: 833 Chestnut St Ste 301, Philadelphia, PA 19107 Phone: 215-955-7190 | |
Meng-chao Lee, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 7500 Central Ave Ste 104, Philadelphia, PA 19111 Phone: 215-742-0712 Fax: 215-742-5218 | |
Carol Bowes-lawlor, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 33 E Chestnut Hill Ave, Philadelphia, PA 19118 Phone: 215-753-9080 Fax: 215-753-8830 | |
Dr. Seung Hee Hong, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2301 E Allegheny Ave, Suite 150, Philadelphia, PA 19134 Phone: 215-926-3535 Fax: 215-926-3536 | |
Dr. Denise Hamilton Christian, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 251 E Bringhurst St, Philadelphia, PA 19144 Phone: 215-844-1020 Fax: 215-844-8147 | |
Mara Leyzin, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 8025 Castor Ave, Philadelphia, PA 19152 Phone: 215-745-9900 Fax: 215-745-9902 |